REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regenxbio (RGNX) Tops Q4 EPS by 45c, Revenues Beat
February 27, 2019 4:24 PM ESTRegenxbio (NASDAQ: RGNX) reported Q4 EPS of $0.11, $0.45 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $40.78 million versus the consensus estimate of $17.33 million.
Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMDCompleted dosing of six additional subjects in the fourth cohort for a total of 12 subjects; 30 subjects dosed across four cohorts in the trialOn-track to initiate Phase IIb trial for wet AMD in late 2019Continues to advance development of RGX-314 for other chronic retinal diseases; new IND submission for... More